AI assistant
Abliva Share Issue/Capital Change 2022
3131_rns_2022-01-14_b93132b9-db38-43e5-97b8-e780fb7d6b78.pdf
Share Issue/Capital Change
Open in viewerOpens in your device viewer
Resolution at the Extraordinary General Meeting in Abliva AB (publ)
Abliva AB (Nasdaq Stockholm: ABLI) ("Abliva" or the "Company") has today held an Extraordinary General Meeting. A summary of the resolution follows. The resolution was passed unanimously.
Approval of the Board of Directors' resolution on a directed issue of convertibles
Today, the Extraordinary General Meeting approved the Board of Directors' resolution from 20 December 2021 that the Company raise a convertible loan in a nominal amount not exceeding SEK 26,000,000 through a directed issue of convertible bonds (the "Convertible Bond 2021 /2022").
Entitled to subscribe for the convertible bonds in the issue shall be the major shareholders Hadean Capital I AS and HVentures Capital I AB, both funds managed by Hadean Ventures.
The convertible issue consists of 260 convertible bonds at a nominal value of SEK 100,000 per convertible bond (the "Convertibles"). The subscription price shall be equal to the nominal value of the Convertibles with a deduction of a set-up fee of 3.95 percent. The Convertibles carries an annual interest rate of 10 percent of their nominal value.
Subscription through payment for the Convertibles shall take place within fifteen (15) banking days of the date of the general meeting approving the resolution to issue the Convertibles. The Board of Directors shall be entitled to extend the subscription and the payment period.
The term of the Convertibles is 12 months with a maturity date on 20 December 2022, to the extent conversion has not taken place before such date. The conversion price will either be (i) same price as other investors in a potential capital raise conducted before 2022-05-22, or (ii) 10-day VWAP prior to conversion request date.
In case of full conversion of the Convertibles on the last day for conversion, the issue entails an increase of the share capital of not more than SEK 6,500,000 excluding conversion of accrued interest. Upon conversion of the capital amount, accrued interest will however also be converted. Provided that conversion occurs on the last day for conversion, the issue entails an increase of the share capital of not more than SEK 7,103,505.
Press Release
Abliva AB (publ), 556595-6538 14 January 2022 11:50:00 CET - Lund, Sweden
For more information, please contact:
Catharina Johansson, Deputy CEO, CFO & VP Investor Relations +46 (0)46-275 62 21, [email protected]
Abliva AB (publ)
Medicon Village, SE-223 81 Lund, Sweden Tel: +46 (0)46 275 62 20 (switchboard) [email protected], www.abliva.com
Subscribe to our news: https://abliva.com/posts/news-subscription/ Follow us on LinkedIn:https://www.linkedin.com/company/abliva Subscribe to our YouTube channel: https://www.youtube.com/channel /UChqP7Ky5caXtp72CELhD6Mg
Abliva – Delivering mitochondrial health
Abliva develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, do not function properly. The company is focused on two projects. KL1333, a powerful NAD⁺ regulator, is in clinical development and has been granted orphan drug designation in Europe and the US. NV354, an energy replacement (succinate) therapy, will enter the clinic in 2022. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI).
Attachments
Resolution at the Extraordinary General Meeting in Abliva AB (publ)